These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 35879192)
21. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Carol H; Szymanska B; Evans K; Boehm I; Houghton PJ; Smith MA; Lock RB Clin Cancer Res; 2013 Apr; 19(7):1795-805. PubMed ID: 23426279 [TBL] [Abstract][Full Text] [Related]
22. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847 [TBL] [Abstract][Full Text] [Related]
23. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of Yang L; Qiu Q; Tang M; Wang F; Yi Y; Yi D; Yang Z; Zhu Z; Zheng S; Yang J; Pei H; Zheng L; Chen Y; Gou L; Luo L; Deng X; Ye H; Hu Y; Niu T; Chen L Clin Cancer Res; 2019 Dec; 25(24):7527-7539. PubMed ID: 31439580 [TBL] [Abstract][Full Text] [Related]
24. An Fc-engineered CD19 antibody eradicates MRD in patient-derived Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205 [TBL] [Abstract][Full Text] [Related]
25. [Knowledge and practice of patient-derived xenograft models in leukemia]. Kato I Rinsho Ketsueki; 2022; 63(9):1335-1343. PubMed ID: 36198560 [TBL] [Abstract][Full Text] [Related]
29. A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. El-Hoss J; Jing D; Evans K; Toscan C; Xie J; Lee H; Taylor RA; Lawrence MG; Risbridger GP; MacKenzie KL; Sutton R; Lock RB Oncotarget; 2016 Sep; 7(37):60475-60490. PubMed ID: 27528024 [TBL] [Abstract][Full Text] [Related]
30. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors. Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381 [TBL] [Abstract][Full Text] [Related]
31. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer. Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209 [TBL] [Abstract][Full Text] [Related]
32. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878 [TBL] [Abstract][Full Text] [Related]
35. Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. Jones L; Richmond J; Evans K; Carol H; Jing D; Kurmasheva RT; Billups CA; Houghton PJ; Smith MA; Lock RB Clin Cancer Res; 2017 Jul; 23(14):3744-3755. PubMed ID: 28119366 [No Abstract] [Full Text] [Related]
39. EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. Martins-Filho SN; Weiss J; Pham NA; Li Q; Cabanero M; Fares A; Stewart EL; Shi R; Patel D; Pal P; McConnell J; Bradbury PA; Sacher AG; Leighl NB; Grindlay A; Allison F; Li M; Yasufuku K; Shepherd FA; Moghal N; Tsao MS; Liu G Lung Cancer; 2020 Jul; 145():144-151. PubMed ID: 32447118 [TBL] [Abstract][Full Text] [Related]
40. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Irving J; Matheson E; Minto L; Blair H; Case M; Halsey C; Swidenbank I; Ponthan F; Kirschner-Schwabe R; Groeneveld-Krentz S; Hof J; Allan J; Harrison C; Vormoor J; von Stackelberg A; Eckert C Blood; 2014 Nov; 124(23):3420-30. PubMed ID: 25253770 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]